Yesilkaya Funda, Tastekin Didem, Saadoni Hani Al, Ergen Arzu, Pence Sadrettin
Department of Molecular Medicine, Istanbul University, Aziz Sancar Institute of Experimental Medicine, Istanbul, Turkey.
Department of Medical Oncology, Istanbul University, Institute of Oncology, Istanbul, Turkey.
North Clin Istanb. 2019 Nov 21;7(1):1-5. doi: 10.14744/nci.2019.26780. eCollection 2020.
Colorectal cancer (CRC) is the third most common type of cancer observed in cancer-related mortality because it has a high metastasis ratio. This study aims to investigate the expression levels of several genes, including metastasis-related colon cancer 1 (MACC1), Filamin A (FLNA), F-box/WD repeat-containing protein 7 (FBXW7), which has an important role in cell signaling, migration and adhesion through the remodeling of the cell skeleton.
In this study, 21 patients with a precise diagnosis of CRC and 21 controls were included. Gene expressions were examined using the RT-PCR technique. To define the relationship of the genes with metastasis, blood samples were collected from all patients with colon/rectal cancer diagnosis without metastasis at six months before and after the medication with Xelox.
Our findings showed that no significant difference was observed in the pre-treatment values compared to the control group, whereas FLNA (p=0.001) expression was observed to be significantly increased following treatment with Xelox.
To our knowledge, our study is the first study to investigate the effects of Xelox treatment on the expression levels of MACC1, FBXW7 and FLNA genes in non-metastatic colorectal cancer patients in Turkey.
结直肠癌(CRC)是癌症相关死亡率中第三常见的癌症类型,因为其转移率很高。本研究旨在调查几种基因的表达水平,包括转移相关结肠癌1(MACC1)、细丝蛋白A(FLNA)、含F盒/ WD重复蛋白7(FBXW7),该蛋白通过细胞骨架重塑在细胞信号传导、迁移和黏附中起重要作用。
本研究纳入了21例确诊为CRC的患者和21例对照。使用RT-PCR技术检测基因表达。为了确定这些基因与转移的关系,在使用希罗达(Xelox)治疗前六个月和治疗后,从所有诊断为无转移的结肠癌/直肠癌患者中采集血样。
我们的研究结果表明,与对照组相比,治疗前的值没有观察到显著差异,而在用希罗达(Xelox)治疗后,观察到FLNA(p = 0.001)表达显著增加。
据我们所知,我们的研究是第一项调查希罗达(Xelox)治疗对土耳其非转移性结直肠癌患者MACC1、FBXW7和FLNA基因表达水平影响的研究。